Additional file 1 of Bacterial DnaK reduces the activity of anti-cancer drugs cisplatin and 5FU

Additional file 1: Figure S1. A Direct binding of eM-DnaK to ARV-1502 as determined by surface plasmon resonance (SPR). Association of ARV-1502 at different concentrations on 2274.9 response units of eM-DnaK immobilized on a CM5 biosensor chip proceeded at a flow rate of 35 μL/min for 250 s, followed by a 600 s dissociation in HBS-EP. A preliminary kinetic analysis yielded a Kd value of 1.899e−6M. B ARV-1502 binds to eM-DnaK and does not prevent eM-DnaK entry into HCT116 cells. eM-DnaK was incubated for 3 h with ARV-1502 and then added to HCT116 cells. After 24 h of incubation cells were treated for 48 h with cisplatin. Western blotting analysis shows that eM-DnaK is able to enter into HCT116 cell line despite the binding of ARV-1502 to DnaK and the treatment with cisplatin. Cells not treated with eM-DnaK, ARV-1502 and cisplatin were used as control.